Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study.

By C. Even, J. Delord, K. Price, K. Nakagawa, D. Oh, M. burge, H. Chung, T. Doi, M. Fakih, S. Takahashi and 4 more. 2022

Subfields: Immunology, Oncology, Otorhinolaryngology

Citations in the corpus

• Immunohistochemical Analysis of Potential Therapeutic Targets PRAME, FOLR1, and CLDN18.2 in Salivary Gland Carcinomas (2026, unknown): “However, treatments, such as Trastuzumab deruxtecan for HER2-overexpressing tumors or pembrolizumab for tumors with a high tumor mutational burden (TMB > 10 mutations/megabase) [11], offer potential therapeutic approaches for selected patients [12, 13].”